- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Melatonin Intake Does Not Impact Inflammatory Markers in Diabetic CKD Patients: Study

A recent clinical trial published in the BMC Nutrition journal examined the effects of melatonin supplementation on oxidative stress and inflammatory markers in diabetic patients with chronic kidney disease (CKD). Despite promising early hypotheses, the study found that melatonin supplementation did not produce statistically significant improvements in these health markers.
The trial was conducted over a period of 10 weeks at Shariati Hospital in Tehran, Iran and involved 41 diabetic patients with CKD stages 3 and 4. The participants were randomly assigned to receive either 5 mg of melatonin twice daily or a placebo. This research monitored dietary intake, physical activity, and anthropometric data at baseline and tracked key biomarkers for oxidative stress (TAC, TOS, MDA) and inflammation (IL-6, hs-CRP) before and after the intervention.
While melatonin supplementation appeared to reduce levels of several biomarkers, like malondialdehyde (MDA), total oxidant status (TOS), interleukin-6 (IL-6), and high-sensitivity C-reactive protein (hs-CRP), these reductions did not reach statistical significance. The total antioxidant capacity (TAC) also showed no remarkable improvement.
In the context of Oxidative Stress Markers, the TAC (Total Antioxidant Capacity) reflects the ability of the body to counteract oxidative damage. No significant changes were observed. TOS (Total Oxidant Status) and MDA (Malondialdehyde) are indicators of oxidative stress levels. Although these decreased with melatonin supplementation, the changes were not statistically significant.
The IL-6 (Interleukin-6) is a pro-inflammatory cytokine, and hs-CRP (High-Sensitivity C-Reactive Protein) is a marker of systemic inflammation. Both showed a downward trend after melatonin supplementation, though without significant statistical backing. Despite the absence of conclusive results, the study reported no adverse effects from melatonin use.
This research emphasized the need for further investigations with larger sample sizes, higher doses of melatonin, and extended study durations to clarify the supplement's potential benefits for diabetic CKD patients. The findings hold clinical relevance given the growing interest in antioxidant therapies for chronic diseases like CKD, where inflammation and oxidative stress play a crucial role.
Overall, this study adds to the ongoing data by highlighting the importance of robust evidence before recommending melatonin as an effective intervention. Further research could explore optimized dosages and combinations of antioxidants. Meanwhile, this trial offers valuable insights into the nuanced role of melatonin in managing complex metabolic conditions.
Source:
Sadeghi, S., Nassiri, A., Hakemi, M. S., Hosseini, F., Pourrezagholie, F., Naeini, F., Niri, A. N., Imani, H., & Mohammadi, H. (2025). Effects of melatonin supplementation on oxidative stress, and inflammatory biomarkers in diabetic patients with chronic kidney disease: a double-blind, randomized controlled trial. BMC Nutrition, 11(1). https://doi.org/10.1186/s40795-025-01026-0
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751